{"DataElement":{"publicId":"5073119","version":"1","preferredName":"Antiviral Agent Administered Type","preferredDefinition":"A description of the antiviral agent that was administered.","longName":"4722990v1.0:5073167v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"4722990","version":"1","preferredName":"Antiviral Agent Administered","preferredDefinition":"Drugs used to treat infections caused by viruses._The act of having given something (e.g., a medication or test).","longName":"4722988v1.0:2233610v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"4722988","version":"1","preferredName":"Antiviral Agent","preferredDefinition":"Drugs used to treat infections caused by viruses.","longName":"C281","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antiviral Agent","conceptCode":"C281","definition":"Any agent that can treat or prevent viral infections by interfering with the viral replication cycle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FC1443D-AF71-FC99-E050-BB89AD434ED4","latestVersionIndicator":"Yes","beginDate":"2015-02-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-02-23","modifiedBy":"ONEDATA","dateModified":"2015-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FC1443D-AF7F-FC99-E050-BB89AD434ED4","latestVersionIndicator":"Yes","beginDate":"2015-02-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-02-23","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5073167","version":"1","preferredName":"Antiviral Agent Type","preferredDefinition":"Drugs used to treat infections caused by viruses._Something distinguishable as an identifiable class based on common qualities.","longName":"5073167v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Valacyclovir","valueDescription":"Valacyclovir","ValueMeaning":{"publicId":"2743501","version":"1","preferredName":"Valacyclovir","longName":"2743501","preferredDefinition":"The hydrochloride salt of the L-valyl ester of the antiviral drug acyclovir. Orally administered, valacyclovir is rapidly converted to acyclovir which inhibits viral DNA replication after further conversion to the nucleotide analog acyclovir triphosphate by viral thymidine kinase, cellular guanyl cyclase, and a number of other cellular enzymes. Acyclovir triphosphate competitively inhibits viral DNA polymerase; incorporates into and terminates the growing viral DNA chain; and inactivates viral DNA polymerase. The greater antiviral activity of acyclovir against herpes simplex virus (HSV) compared with varicella-zoster virus (VZV) is due to its more efficient phosphorylation by HSV thymidine kinase.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Valacyclovir","conceptCode":"C28235","definition":"The hydrochloride salt of the L-valyl ester of the antiviral drug acyclovir. Orally administered, valacyclovir is rapidly converted to acyclovir which inhibits viral DNA replication after further conversion to the nucleotide analog acyclovir triphosphate by viral thymidine kinase, cellular guanyl cyclase, and a number of other cellular enzymes. Acyclovir triphosphate competitively inhibits viral DNA polymerase; incorporates into and terminates the growing viral DNA chain; and inactivates viral DNA polymerase. The greater antiviral activity of acyclovir against herpes simplex virus (HSV) compared with varicella-zoster virus (VZV) is due to its more efficient phosphorylation by HSV thymidine kinase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B3433CB-B6A5-3213-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-19","modifiedBy":"COOPERM","dateModified":"2018-03-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"26182977-43E6-CFC1-E050-BB89AD434457","beginDate":"2015-12-04","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-17","modifiedBy":"GDEEN","dateModified":"2023-04-17","deletedIndicator":"No"},{"value":"Acyclovir","valueDescription":"Acyclovir","ValueMeaning":{"publicId":"5073168","version":"1","preferredName":"Acyclovir","longName":"5073168","preferredDefinition":"A synthetic analog of the purine nucleoside, guanosine, with potent antiviral activity against herpes simplex viruses type 1 and 2, varicella-zoster virus and other viruses of the herpesvirus family. After conversion in vivo to the active metabolite acyclovir triphosphate by viral thymidine kinase, acyclovir competitively inhibits viral DNA polymerase by incorporating into the growing viral DNA chain and terminating further polymerization.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acyclovir","conceptCode":"C205","definition":"A synthetic analog of the purine nucleoside, guanosine, with potent antiviral activity against herpes simplex viruses type 1 and 2, varicella-zoster virus and other viruses of the herpesvirus family. After conversion in vivo to the active metabolite acyclovir triphosphate by viral thymidine kinase, acyclovir competitively inhibits viral DNA polymerase by incorporating into the growing viral DNA chain and terminating further polymerization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"26182977-43F0-CFC1-E050-BB89AD434457","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"26182977-4408-CFC1-E050-BB89AD434457","beginDate":"2015-12-04","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-17","modifiedBy":"GDEEN","dateModified":"2023-04-17","deletedIndicator":"No"},{"value":"Valganciclovir","valueDescription":"Valganciclovir","ValueMeaning":{"publicId":"2575724","version":"1","preferredName":"Valganciclovir","longName":"2575724","preferredDefinition":"A synthetic prodrug of ganciclovir, a nucleoside analogue of 2'-deoxyguanosine, with antiviral activity. After phosphorylation, valganciclovir is incorporated into DNA, resulting in inhibition of viral DNA polymerase, viral DNA synthesis, and viral replication. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Valganciclovir","conceptCode":"C2629","definition":"A synthetic prodrug of ganciclovir, a nucleoside analogue of 2'-deoxyguanosine, with antiviral activity. After phosphorylation, valganciclovir is incorporated into DNA, resulting in inhibition of viral DNA polymerase, viral DNA synthesis, and viral replication. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4D9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"COOPERM","dateModified":"2018-03-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"26182977-4414-CFC1-E050-BB89AD434457","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"ONEDATA","dateModified":"2015-12-04","deletedIndicator":"No"},{"value":"Ganciclovir","valueDescription":"Ganciclovir","ValueMeaning":{"publicId":"2575684","version":"1","preferredName":"Ganciclovir","longName":"2575684","preferredDefinition":"A synthetic guanine derivative with antiviral activity.  As the active metabolite of ganciclovir, ganciclovir-5-triphosphate (ganciclovir-TP) appears to inhibit viral DNA synthesis by competitive inhibition of viral DNA polymerases and incorporation into viral DNA, resulting in eventual termination of viral DNA elongation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ganciclovir","conceptCode":"C517","definition":"A synthetic guanine derivative with antiviral activity.  As the active metabolite of ganciclovir, ganciclovir-5-triphosphate (ganciclovir-TP) appears to inhibit viral DNA synthesis by competitive inhibition of viral DNA polymerases and incorporation into viral DNA, resulting in eventual termination of viral DNA elongation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4B1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"26182977-441E-CFC1-E050-BB89AD434457","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"ONEDATA","dateModified":"2015-12-04","deletedIndicator":"No"},{"value":"Famciclovir","valueDescription":"Famciclovir","ValueMeaning":{"publicId":"2575683","version":"1","preferredName":"Famciclovir","longName":"2575683","preferredDefinition":"A diacetyl 6-deoxy prodrug analog of the antiviral agent penciclovir.  Orally administered, famciclovir in vivo is converted to penciclovir triphosphate, which is active against the Herpes viruses, including herpes simplex 1 and 2 and varicella-zoster.  This agent inhibits the replication of viral DNA by interfering competitively with DNA polymerase. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Famciclovir","conceptCode":"C29044","definition":"A diacetyl 6-deoxy prodrug analog of the antiviral agent penciclovir.  Orally administered, famciclovir in vivo is converted to penciclovir triphosphate, which is active against the Herpes viruses, including herpes simplex 1 and 2 and varicella-zoster.  This agent inhibits the replication of viral DNA by interfering competitively with DNA polymerase. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4B0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"26182977-4428-CFC1-E050-BB89AD434457","beginDate":"2015-12-04","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-17","modifiedBy":"GDEEN","dateModified":"2023-04-17","deletedIndicator":"No"},{"value":"None","valueDescription":"None","ValueMeaning":{"publicId":"2577064","version":"1","preferredName":"None","longName":"2577064","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA15-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"261938BC-01BD-DBF7-E050-BB89AD4347C5","beginDate":"2015-12-04","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-17","modifiedBy":"GDEEN","dateModified":"2023-04-17","deletedIndicator":"No"},{"value":"Other antiviral drug","valueDescription":"Other Antiviral Agent","ValueMeaning":{"publicId":"5073181","version":"1","preferredName":"Other Antiviral Agent","longName":"5073181v1.00","preferredDefinition":"Different than the one(s) previously specified or mentioned._Any agent that can treat or prevent viral infections by interfering with the viral replication cycle.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antiviral Agent","conceptCode":"C281","definition":"Any agent that can treat or prevent viral infections by interfering with the viral replication cycle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"261938BC-01C7-DBF7-E050-BB89AD4347C5","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"GDEEN","dateModified":"2023-04-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"261938BC-01DF-DBF7-E050-BB89AD4347C5","beginDate":"2015-12-04","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-17","modifiedBy":"GDEEN","dateModified":"2023-04-17","deletedIndicator":"No"},{"value":"Letermovir","valueDescription":"Letermovir","ValueMeaning":{"publicId":"5073183","version":"1","preferredName":"Letermovir","longName":"5073183","preferredDefinition":"An orally bioavailable, non-nucleoside, 3,4-dihydroquinazolinyl acetic acid and inhibitor of the pUL56 subunit of the viral terminase complex of cytomegalovirus (CMV), with potential CMV-specific antiviral activity. Upon oral administration, letermovir binds to the pUL56 subunit of the viral terminase complex of CMV and prevents the cleavage of concatemeric DNA into monomeric genome length DNA. As this agent interferes with viral DNA processing and subsequent viral DNA packaging into procapsids, CMV replication is blocked and CMV infection is prevented.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Letermovir","conceptCode":"C115099","definition":"An orally bioavailable, non-nucleoside, 3,4-dihydroquinazolinyl acetic acid and inhibitor of the pUL56 subunit of the viral terminase complex of cytomegalovirus (CMV), with potential CMV-specific antiviral activity. Upon oral administration, letermovir binds to the pUL56 subunit of the viral terminase complex of CMV and prevents the cleavage of concatemeric DNA into monomeric genome length DNA. As this agent interferes with viral DNA processing and subsequent viral DNA packaging into procapsids, CMV replication is blocked and CMV infection is prevented.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"261938BC-01EC-DBF7-E050-BB89AD4347C5","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"COOPERM","dateModified":"2019-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"261938BC-0205-DBF7-E050-BB89AD4347C5","beginDate":"2015-12-04","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-17","modifiedBy":"GDEEN","dateModified":"2023-04-17","deletedIndicator":"No"},{"value":"Brincidofovir","valueDescription":"Brincidofovir","ValueMeaning":{"publicId":"5073185","version":"1","preferredName":"Brincidofovir","longName":"5073185","preferredDefinition":"An alkoxyalkyl ester prodrug containing the synthetic, acyclic nucleoside monophosphate analog cidofovir linked, through its phosphonate group, to a lipid, 3-hexadecyloxy-1-propanol, with antiviral activity against double-stranded DNA viruses. Upon oral administration, brincidofovir crosses the intestinal wall and penetrates target viral-infected cells before being cleaved to the free antiviral agent cidofovir. In turn, cidofovir is phosphorylated by pyruvate kinases to its active metabolite cidofovir diphosphate. Cidofovir diphosphate, bearing structural similarity to nucleotides, competes with deoxycytosine-5-triphosphate (dCTP) for viral DNA polymerase and gets incorporated into the growing viral DNA strands. As a result, it prevents further DNA polymerization and disrupts DNA replication of viruses. Compared to cidofovir, which is given intravenously, hexadecyloxypropyl-cidofovir shows better oral bioavailability, less toxicity and enhanced cellular penetration.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brincidofovir","conceptCode":"C90587","definition":"An alkoxyalkyl ester prodrug containing the synthetic, acyclic nucleoside monophosphate analog cidofovir linked, through its phosphonate group, to a lipid, 3-hexadecyloxy-1-propanol, with antiviral activity against double-stranded DNA viruses. Upon oral administration, brincidofovir crosses the intestinal wall and penetrates target viral-infected cells before being cleaved to the free antiviral agent cidofovir. In turn, cidofovir is phosphorylated by pyruvate kinases to its active metabolite cidofovir diphosphate. Cidofovir diphosphate, bearing structural similarity to nucleotides, competes with deoxycytosine-5-triphosphate (dCTP) for viral DNA polymerase and gets incorporated into the growing viral DNA strands. As a result, it prevents further DNA polymerization and disrupts DNA replication of viruses. Compared to cidofovir, which is given intravenously, hexadecyloxypropyl-cidofovir shows better oral bioavailability, less toxicity and enhanced cellular penetration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"261938BC-0212-DBF7-E050-BB89AD4347C5","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"261938BC-022B-DBF7-E050-BB89AD4347C5","beginDate":"2015-12-04","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-17","modifiedBy":"GDEEN","dateModified":"2023-04-17","deletedIndicator":"No"},{"value":"Zanamivir","valueDescription":"Zanamivir","ValueMeaning":{"publicId":"5633387","version":"1","preferredName":"Zanamivir","longName":"5633387","preferredDefinition":"A sialic acid-analogue neuraminidase inhibitor with antiviral activity. Administered into the respiratory tract by aerosol inhalation, zanamivir selectively binds to and inhibits influenza A and B virus neuraminidase-mediated cleavage of sialic acid residues in host cell membrane-bound glycoprotein receptors for influenza viruses, preventing the release of progeny viruses from host cell surfaces and, so, further viral replication.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zanamivir","conceptCode":"C47786","definition":"A sialic acid-analogue neuraminidase inhibitor with antiviral activity. Administered into the respiratory tract by aerosol inhalation, zanamivir selectively binds to and inhibits influenza A and B virus neuraminidase-mediated cleavage of sialic acid residues in host cell membrane-bound glycoprotein receptors for influenza viruses, preventing the release of progeny viruses from host cell surfaces and, so, further viral replication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46EDA67D-D6E7-41DC-E053-F662850A0513","latestVersionIndicator":"Yes","beginDate":"2017-01-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-01-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"46F354A1-88A0-01A4-E053-F662850AC086","beginDate":"2017-01-25","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-17","modifiedBy":"GDEEN","dateModified":"2023-04-17","deletedIndicator":"No"},{"value":"Rimantadine","valueDescription":"Rimantadine","ValueMeaning":{"publicId":"5633389","version":"1","preferredName":"Rimantadine","longName":"5633389","preferredDefinition":"A cyclic amine and alpha-methyl derivative of amantadine with antiviral activity. Although the exact mechanism of action of rimantadine is not understood, this agent appears to exert its antiviral effect against influenza A virus by interfering with the function of the transmembrane domain of the viral M2 protein, thereby preventing the uncoating of the virus and subsequent release of infectious viral nucleic acids into the cytoplasm of infected cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rimantadine","conceptCode":"C61927","definition":"A cyclic amine and alpha-methyl derivative of amantadine with antiviral activity. Although the exact mechanism of action of rimantadine is not understood, this agent appears to exert its antiviral effect against influenza A virus by interfering with the function of the transmembrane domain of the viral M2 protein, thereby preventing the uncoating of the virus and subsequent release of infectious viral nucleic acids into the cytoplasm of infected cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46EDA67D-D70D-41DC-E053-F662850A0513","latestVersionIndicator":"Yes","beginDate":"2017-01-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-01-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"46F354A1-88B4-01A4-E053-F662850AC086","beginDate":"2017-01-25","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-17","modifiedBy":"GDEEN","dateModified":"2023-04-17","deletedIndicator":"No"},{"value":"Ribavirin","valueDescription":"Ribavirin","ValueMeaning":{"publicId":"5633390","version":"1","preferredName":"Ribavirin","longName":"5633390","preferredDefinition":"A synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses. Ribavirin is incorporated into viral RNA, thereby inhibiting viral RNA synthesis, inducing viral genome mutations, and inhibiting normal viral replication.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ribavirin","conceptCode":"C807","definition":"A synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses. Ribavirin is incorporated into viral RNA, thereby inhibiting viral RNA synthesis, inducing viral genome mutations, and inhibiting normal viral replication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46EDA67D-D730-41DC-E053-F662850A0513","latestVersionIndicator":"Yes","beginDate":"2017-01-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-01-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"46F354A1-88C8-01A4-E053-F662850AC086","beginDate":"2017-01-25","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-17","modifiedBy":"GDEEN","dateModified":"2023-04-17","deletedIndicator":"No"},{"value":"Palivizumab","valueDescription":"Palivizumab","ValueMeaning":{"publicId":"5633392","version":"1","preferredName":"Palivizumab","longName":"5633392","preferredDefinition":"A humanized monoclonal antibody against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with prophylactic application in respiratory syncytial virus infections. RSV F protein, a small envelop glycoprotein, is not only required for cytopathic syncytia resulting from cell-to-cell fusion, but is also necessary for viral spreading and evading neutralizing antibody. Palivizumab neutralizes and inhibits fusion activity of RSV, thereby preventing syncytia formation. Administration of this antibody does not interfere with other immunizations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Palivizumab","conceptCode":"C2625","definition":"A humanized monoclonal antibody against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with prophylactic application in respiratory syncytial virus infections. RSV F protein, a small envelop glycoprotein, is not only required for cytopathic syncytia resulting from cell-to-cell fusion, but is also necessary for viral spreading and evading neutralizing antibody. Palivizumab neutralizes and inhibits fusion activity of RSV, thereby preventing syncytia formation. Administration of this antibody does not interfere with other immunizations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46EDA67D-D755-41DC-E053-F662850A0513","latestVersionIndicator":"Yes","beginDate":"2017-01-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-01-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"46F354A1-88DC-01A4-E053-F662850AC086","beginDate":"2017-01-25","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-17","modifiedBy":"GDEEN","dateModified":"2023-04-17","deletedIndicator":"No"},{"value":"Peramivir","valueDescription":"Peramivir","ValueMeaning":{"publicId":"5633394","version":"1","preferredName":"Peramivir","longName":"5633394","preferredDefinition":"A cyclopentane derivative with activity against influenza A and B viruses. Peramivir is a neuraminidase inhibitor which prevents normal processing of virus particles such that virus particles are not released from infected cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peramivir","conceptCode":"C81611","definition":"A cyclopentane derivative with activity against influenza A and B viruses. Peramivir is a neuraminidase inhibitor which prevents normal processing of virus particles such that virus particles are not released from infected cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46EDA67D-D77B-41DC-E053-F662850A0513","latestVersionIndicator":"Yes","beginDate":"2017-01-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-01-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"46F354A1-88F0-01A4-E053-F662850AC086","beginDate":"2017-01-25","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-17","modifiedBy":"GDEEN","dateModified":"2023-04-17","deletedIndicator":"No"},{"value":"Oseltamivir","valueDescription":"Oseltamivir","ValueMeaning":{"publicId":"5633395","version":"1","preferredName":"Oseltamivir","longName":"5633395","preferredDefinition":"A synthetic derivative prodrug of ethyl ester with antiviral activity. Osetamivir blocks neuraminidases on the surfaces of influenza viruses, interfering with host cell release of complete viral particles.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oseltamivir","conceptCode":"C62061","definition":"A synthetic derivative prodrug of ethyl ester with antiviral activity. Osetamivir blocks neuraminidases on the surfaces of influenza viruses, interfering with host cell release of complete viral particles.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46EDA67D-D79E-41DC-E053-F662850A0513","latestVersionIndicator":"Yes","beginDate":"2017-01-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-01-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"46F354A1-8904-01A4-E053-F662850AC086","beginDate":"2017-01-25","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-17","modifiedBy":"GDEEN","dateModified":"2023-04-17","deletedIndicator":"No"},{"value":"Amantadine","valueDescription":"Amantadine","ValueMeaning":{"publicId":"5633397","version":"1","preferredName":"Amantadine","longName":"5633397","preferredDefinition":"A synthetic tricyclic amine with antiviral, antiparkinsonian, and antihyperalgesic activities. Amantadine appears to exert its antiviral effect against the influenza A virus by interfering with the function of the transmembrane domain of the viral M2 protein, thereby preventing the release of infectious viral nucleic acids into host cells. Furthermore, this agent prevents virus assembly during virus replication. Amantadine exerts its antiparkinsonian effects by stimulating the release of dopamine from striatal dopaminergic nerve terminals and inhibiting its pre-synaptic reuptake. This agent may also exert some anticholinergic effect through inhibition of N-methyl-D-aspartic acid (NMDA) receptor-mediated stimulation of acetylcholine, resulting in antihyperalgesia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amantadine","conceptCode":"C61632","definition":"A synthetic tricyclic amine with antiviral, antiparkinsonian, and antihyperalgesic activities. Amantadine appears to exert its antiviral effect against the influenza A virus by interfering with the function of the transmembrane domain of the viral M2 protein, thereby preventing the release of infectious viral nucleic acids into host cells. Furthermore, this agent prevents virus assembly during virus replication. Amantadine exerts its antiparkinsonian effects by stimulating the release of dopamine from striatal dopaminergic nerve terminals and inhibiting its pre-synaptic reuptake. This agent may also exert some anticholinergic effect through inhibition of N-methyl-D-aspartic acid (NMDA) receptor-mediated stimulation of acetylcholine, resulting in antihyperalgesia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46EDA67D-D7C3-41DC-E053-F662850A0513","latestVersionIndicator":"Yes","beginDate":"2017-01-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-01-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"46F354A1-8918-01A4-E053-F662850AC086","beginDate":"2017-01-25","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-17","modifiedBy":"GDEEN","dateModified":"2023-04-17","deletedIndicator":"No"},{"value":"Maribavir","valueDescription":"Maribavir","ValueMeaning":{"publicId":"5632012","version":"1","preferredName":"Maribavir","longName":"5632012","preferredDefinition":"An orally available benzimidazole riboside compound with activity against cytomegalovirus (CMV). Maribavir is a selective ATP competitor of viral UL97 kinase, which is involved in viral nuclear maturation events, such as viral DNA assembly and movement of viral capsids from the nucleus of infected cells. Maribavir has activity against strains of CMV that are resistant to standard anti-CMV agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Maribavir","conceptCode":"C82254","definition":"An orally available benzimidazole riboside compound with activity against cytomegalovirus (CMV). Maribavir is a selective ATP competitor of viral UL97 kinase, which is involved in viral nuclear maturation events, such as viral DNA assembly and movement of viral capsids from the nucleus of infected cells. Maribavir has activity against strains of CMV that are resistant to standard anti-CMV agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"468C6C05-CDA5-0CF5-E053-F662850A61A4","latestVersionIndicator":"Yes","beginDate":"2017-01-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-01-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"468C6C05-CDBE-0CF5-E053-F662850A61A4","beginDate":"2017-01-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-01-20","modifiedBy":"ONEDATA","dateModified":"2017-01-20","deletedIndicator":"No"},{"value":"Cidofovir","valueDescription":"Cidofovir","ValueMeaning":{"publicId":"5632014","version":"1","preferredName":"Cidofovir","longName":"5632014","preferredDefinition":"A synthetic, acyclic, monophosphate nucleotide analog of deoxycytidine with antiviral activity, and mostly used against cytomegalovirus (CMV). After incorporation into the host cell, cidofovir is phosphorylated by pyruvate kinases to its active metabolite cidofovir diphosphate. Cidofovir diphosphate, bearing structural similarity to nucleotides, competes with deoxycytosine-5-triphosphate (dCTP) for viral DNA polymerase and gets incorporated into the growing viral DNA strands. As a result, it prevents further DNA polymerization and disrupts DNA replication of viruses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cidofovir","conceptCode":"C1600","definition":"A synthetic, acyclic, monophosphate nucleotide analog of deoxycytidine with antiviral activity, and mostly used against cytomegalovirus (CMV). After incorporation into the host cell, cidofovir is phosphorylated by pyruvate kinases to its active metabolite cidofovir diphosphate. Cidofovir diphosphate, bearing structural similarity to nucleotides, competes with deoxycytosine-5-triphosphate (dCTP) for viral DNA polymerase and gets incorporated into the growing viral DNA strands. As a result, it prevents further DNA polymerization and disrupts DNA replication of viruses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"468C6C05-CDEA-0CF5-E053-F662850A61A4","latestVersionIndicator":"Yes","beginDate":"2017-01-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-01-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"468C6C05-CE02-0CF5-E053-F662850A61A4","beginDate":"2017-01-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-01-20","modifiedBy":"ONEDATA","dateModified":"2017-01-20","deletedIndicator":"No"},{"value":"Foscarnet","valueDescription":"Foscarnet","ValueMeaning":{"publicId":"5632013","version":"1","preferredName":"Foscarnet","longName":"5632013","preferredDefinition":"A synthetic organic analog of inorganic pyrophosphate with activity against several types of viruses, but primarily used for the treatment of cytomegalovirus retinitis. Foscarnet selectively blocks the pyrophosphate binding site of virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases. Because this agent crosses the blood brain barrier, it may be used in the treatment of viral infections of the central nervous system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Foscarnet","conceptCode":"C71630","definition":"A synthetic organic analog of inorganic pyrophosphate with activity against several types of viruses, but primarily used for the treatment of cytomegalovirus retinitis. Foscarnet selectively blocks the pyrophosphate binding site of virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases. Because this agent crosses the blood brain barrier, it may be used in the treatment of viral infections of the central nervous system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"468C6C05-CDC8-0CF5-E053-F662850A61A4","latestVersionIndicator":"Yes","beginDate":"2017-01-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-01-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5AE12BB7-5AC3-6A52-E053-F662850ABB22","beginDate":"2017-01-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-06","modifiedBy":"ONEDATA","dateModified":"2017-10-06","deletedIndicator":"No"},{"value":"Cytogam/IVIG","valueDescription":null,"ValueMeaning":{"publicId":"13368987","version":"1","preferredName":"Human Cytomegalovirus Immune Globulin And/Or Intravenous Immunoglobulin Therapy","longName":"13368987v1.00","preferredDefinition":"A sterilized solution containing immunoglobulins (IGs) against cytomegalovirus (CMV) that is derived from human plasma of donors infected with CMV and can be used for passive immunization against CMV. Upon administration, human CMVIG is used to help prevent or treat infection by CMV._Used to indicate that either or both of two items or options may be valid._The administration of a blood product derived from pooled IgG antibodies extracted from donor plasma delivered intravenously. It is used to treat multiple disorders, including immunodeficiencies, autoimmune disorders, and active infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Human Cytomegalovirus Immune Globulin","conceptCode":"C80826","definition":"A sterilized solution containing immunoglobulins (IGs) against cytomegalovirus (CMV) that is derived from human plasma of donors infected with CMV and can be used for passive immunization against CMV. Upon administration, human CMVIG is used to help prevent or treat infection by CMV.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And/Or","conceptCode":"C48928","definition":"Used to indicate that either or both of two items or options may be valid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Intravenous Immunoglobulin Therapy","conceptCode":"C121331","definition":"The administration of a blood product derived from pooled IgG antibodies extracted from donor plasma delivered intravenously. It is used to treat multiple disorders, including immunodeficiencies, autoimmune disorders, and active infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9912683-2E83-0209-E053-731AD00A722A","latestVersionIndicator":"Yes","beginDate":"2023-04-17","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-17","modifiedBy":"GDEEN","dateModified":"2023-04-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F9912683-2E85-0209-E053-731AD00A722A","beginDate":"2023-04-17","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-17","modifiedBy":"GDEEN","dateModified":"2023-04-17","deletedIndicator":"No"},{"value":"Leflunomide","valueDescription":null,"ValueMeaning":{"publicId":"13368988","version":"1","preferredName":"Leflunomide","longName":"13368988v1.00","preferredDefinition":"A derivative of isoxazole used for its immunosuppressive and anti-inflammatory properties.  As a prodrug, leflunomide is converted to an active metabolite, A77 1726, which blocks dihydroorotate dehydrogenase, a key enzyme of de novo pyrimidine synthesis, thereby preventing the expansion of activated T lymphocytes.  This agent also inhibits various protein tyrosine kinases, such as protein kinase C (PKC), thereby inhibiting cell proliferation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leflunomide","conceptCode":"C1128","definition":"A derivative of isoxazole used for its immunosuppressive and anti-inflammatory properties.  As a prodrug, leflunomide is converted to an active metabolite, A77 1726, which blocks dihydroorotate dehydrogenase, a key enzyme of de novo pyrimidine synthesis, thereby preventing the expansion of activated T lymphocytes.  This agent also inhibits various protein tyrosine kinases, such as protein kinase C (PKC), thereby inhibiting cell proliferation. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9912683-2E84-0209-E053-731AD00A722A","latestVersionIndicator":"Yes","beginDate":"2023-04-17","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-17","modifiedBy":"GDEEN","dateModified":"2023-04-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F9912683-2E86-0209-E053-731AD00A722A","beginDate":"2023-04-17","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-17","modifiedBy":"GDEEN","dateModified":"2023-04-17","deletedIndicator":"No"},{"value":"Cytotoxic T-Lymphocyte","valueDescription":null,"ValueMeaning":{"publicId":"3453291","version":"1","preferredName":"Cytotoxic T-Lymphocyte","longName":"3453291","preferredDefinition":"Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. These cells are distinct from natural killer cells and from killer cells mediating antibody-dependent cell cytotoxicity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytotoxic T-Lymphocyte","conceptCode":"C12543","definition":"Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. These cells are distinct from natural killer cells and from killer cells mediating antibody-dependent cell cytotoxicity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF8B5855-AC98-B390-E040-BB89AD4333B3","latestVersionIndicator":"Yes","beginDate":"2012-05-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-08","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F9A0425A-5EC3-287A-E053-731AD00AB203","beginDate":"2023-04-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-18","modifiedBy":"GDEEN","dateModified":"2023-04-18","deletedIndicator":"No"},{"value":"Cellular therapy","valueDescription":null,"ValueMeaning":{"publicId":"4666954","version":"1","preferredName":"Cellular Therapy","longName":"4666954","preferredDefinition":"Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cellular Therapy","conceptCode":"C70601","definition":"Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0CA258B6-2CAE-90DB-E050-BB89AD4330D1","latestVersionIndicator":"Yes","beginDate":"2015-01-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-01-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FDF05B59-F479-6806-E053-731AD00A5CEE","beginDate":"2023-06-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-06-12","modifiedBy":"KUMMEROA","dateModified":"2023-06-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5073166","version":"1","preferredName":"Antiviral Agent Type","preferredDefinition":"Drugs used to treat infections caused by viruses.:Something distinguishable as an identifiable class based on common qualities.","longName":"C281:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antiviral Agent","conceptCode":"C281","definition":"Any agent that can treat or prevent viral infections by interfering with the viral replication cycle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"26182977-43BF-CFC1-E050-BB89AD434457","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"ONEDATA","dateModified":"2015-12-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"26182977-43D0-CFC1-E050-BB89AD434457","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"KUMMEROA","dateModified":"2023-06-12","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"HPST_IP_antivirl_agnt_type","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"Antiviral drugs","type":"Alternate Question Text","description":"Antiviral drugs","url":null,"context":"NHLBI"},{"name":"Antiviral drugs","type":"Application Standard Question Text","description":"Antiviral drugs","url":null,"context":"NHLBI"},{"name":"What was the antiviral agent","type":"Preferred Question Text","description":"What was the antiviral agent that was administered?","url":null,"context":"NHLBI"},{"name":"Specify antiviral drugs","type":"Alternate Question Text","description":"Specify antiviral drugs","url":null,"context":"NHLBI"},{"name":"Specify antiviral drug","type":"Alternate Question Text","description":"Specify antiviral drug","url":null,"context":"NHLBI"},{"name":"Specify the first antiviral drug given","type":"Alternate Question Text","description":"Specify the first antiviral drug given","url":null,"context":"NHLBI"},{"name":"COG CRF TEXT 1","type":"Alternate Question Text","description":"Specify agents:","url":null,"context":"COG"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"26182977-4196-CFC1-E050-BB89AD434457","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"GDEEN","dateModified":"2023-04-17","changeDescription":". Added AQT for 2150r1 2018-03-02 SLS. AQT added for 2100r7. 03/25/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}